nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Vandetanib—VEGFA—glaucoma	0.00497	1	CrCbGaD
Afatinib—Back pain—Pilocarpine—glaucoma	0.00109	0.00183	CcSEcCtD
Afatinib—Cough—Brimonidine—glaucoma	0.00109	0.00183	CcSEcCtD
Afatinib—Nausea—Metipranolol—glaucoma	0.00109	0.00183	CcSEcCtD
Afatinib—Epistaxis—Clonidine—glaucoma	0.00109	0.00183	CcSEcCtD
Afatinib—Muscle spasms—Pilocarpine—glaucoma	0.00109	0.00182	CcSEcCtD
Afatinib—Dizziness—Carbachol—glaucoma	0.00108	0.00181	CcSEcCtD
Afatinib—Insomnia—Apraclonidine—glaucoma	0.00108	0.0018	CcSEcCtD
Afatinib—Headache—Carteolol—glaucoma	0.00106	0.00178	CcSEcCtD
Afatinib—Vomiting—Diclofenamide—glaucoma	0.00106	0.00178	CcSEcCtD
Afatinib—Dizziness—Levobunolol—glaucoma	0.00106	0.00178	CcSEcCtD
Afatinib—Dyspnoea—Apraclonidine—glaucoma	0.00106	0.00178	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.00106	0.00177	CcSEcCtD
Afatinib—Pruritus—Latanoprost—glaucoma	0.00105	0.00177	CcSEcCtD
Afatinib—Rash—Diclofenamide—glaucoma	0.00105	0.00177	CcSEcCtD
Afatinib—Diarrhoea—Methazolamide—glaucoma	0.00105	0.00176	CcSEcCtD
Afatinib—Upper respiratory tract infection—Betaxolol—glaucoma	0.00105	0.00176	CcSEcCtD
Afatinib—Headache—Diclofenamide—glaucoma	0.00105	0.00175	CcSEcCtD
Afatinib—Insomnia—Bimatoprost—glaucoma	0.00104	0.00175	CcSEcCtD
Afatinib—Cough—Dorzolamide—glaucoma	0.00104	0.00175	CcSEcCtD
Afatinib—Cough—Travoprost—glaucoma	0.00104	0.00174	CcSEcCtD
Afatinib—Vomiting—Carbachol—glaucoma	0.00104	0.00174	CcSEcCtD
Afatinib—Dyspnoea—Bimatoprost—glaucoma	0.00103	0.00172	CcSEcCtD
Afatinib—Rash—Carbachol—glaucoma	0.00103	0.00172	CcSEcCtD
Afatinib—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00103	0.00172	CcSEcCtD
Afatinib—Dermatitis—Carbachol—glaucoma	0.00103	0.00172	CcSEcCtD
Afatinib—Fatigue—Apraclonidine—glaucoma	0.00103	0.00172	CcSEcCtD
Afatinib—Cough—Brinzolamide—glaucoma	0.00102	0.00172	CcSEcCtD
Afatinib—Headache—Carbachol—glaucoma	0.00102	0.00171	CcSEcCtD
Afatinib—Weight decreased—Betaxolol—glaucoma	0.00102	0.00171	CcSEcCtD
Afatinib—Constipation—Apraclonidine—glaucoma	0.00102	0.00171	CcSEcCtD
Afatinib—Dyspepsia—Bimatoprost—glaucoma	0.00101	0.0017	CcSEcCtD
Afatinib—Infection—Brimonidine—glaucoma	0.00101	0.0017	CcSEcCtD
Afatinib—Pneumonia—Betaxolol—glaucoma	0.00101	0.0017	CcSEcCtD
Afatinib—Nausea—Carteolol—glaucoma	0.00101	0.00169	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.00101	0.00169	CcSEcCtD
Afatinib—Headache—Levobunolol—glaucoma	0.001	0.00169	CcSEcCtD
Afatinib—Infestation NOS—Betaxolol—glaucoma	0.001	0.00169	CcSEcCtD
Afatinib—Infestation—Betaxolol—glaucoma	0.001	0.00169	CcSEcCtD
Afatinib—Nervous system disorder—Brimonidine—glaucoma	0.001	0.00168	CcSEcCtD
Afatinib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000995	0.00167	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000993	0.00167	CcSEcCtD
Afatinib—Skin disorder—Brimonidine—glaucoma	0.000992	0.00166	CcSEcCtD
Afatinib—Nausea—Diclofenamide—glaucoma	0.000991	0.00166	CcSEcCtD
Afatinib—Cough—Pilocarpine—glaucoma	0.000985	0.00165	CcSEcCtD
Afatinib—Dizziness—Latanoprost—glaucoma	0.000984	0.00165	CcSEcCtD
Afatinib—Stomatitis—Betaxolol—glaucoma	0.000979	0.00164	CcSEcCtD
Afatinib—Vomiting—Methazolamide—glaucoma	0.000977	0.00164	CcSEcCtD
Afatinib—Conjunctivitis—Betaxolol—glaucoma	0.000976	0.00164	CcSEcCtD
Afatinib—Rash—Methazolamide—glaucoma	0.000969	0.00163	CcSEcCtD
Afatinib—Dermatitis—Methazolamide—glaucoma	0.000968	0.00162	CcSEcCtD
Afatinib—Eye disorder—Clonidine—glaucoma	0.000968	0.00162	CcSEcCtD
Afatinib—Nausea—Carbachol—glaucoma	0.000968	0.00162	CcSEcCtD
Afatinib—Infection—Travoprost—glaucoma	0.000965	0.00162	CcSEcCtD
Afatinib—Headache—Methazolamide—glaucoma	0.000963	0.00162	CcSEcCtD
Afatinib—Nausea—Levobunolol—glaucoma	0.000953	0.0016	CcSEcCtD
Afatinib—Infection—Brinzolamide—glaucoma	0.000952	0.0016	CcSEcCtD
Afatinib—Nervous system disorder—Travoprost—glaucoma	0.000952	0.0016	CcSEcCtD
Afatinib—Nasopharyngitis—Timolol—glaucoma	0.000952	0.0016	CcSEcCtD
Afatinib—Epistaxis—Betaxolol—glaucoma	0.000947	0.00159	CcSEcCtD
Afatinib—Skin disorder—Travoprost—glaucoma	0.000943	0.00158	CcSEcCtD
Afatinib—Nervous system disorder—Brinzolamide—glaucoma	0.00094	0.00158	CcSEcCtD
Afatinib—Rash—Latanoprost—glaucoma	0.000938	0.00157	CcSEcCtD
Afatinib—Dermatitis—Latanoprost—glaucoma	0.000937	0.00157	CcSEcCtD
Afatinib—Dyspepsia—Acetazolamide—glaucoma	0.000936	0.00157	CcSEcCtD
Afatinib—Mediastinal disorder—Clonidine—glaucoma	0.000933	0.00157	CcSEcCtD
Afatinib—Headache—Latanoprost—glaucoma	0.000932	0.00156	CcSEcCtD
Afatinib—Skin disorder—Brinzolamide—glaucoma	0.000931	0.00156	CcSEcCtD
Afatinib—Decreased appetite—Acetazolamide—glaucoma	0.000925	0.00155	CcSEcCtD
Afatinib—Insomnia—Brimonidine—glaucoma	0.000923	0.00155	CcSEcCtD
Afatinib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000918	0.00154	CcSEcCtD
Afatinib—Fatigue—Acetazolamide—glaucoma	0.000917	0.00154	CcSEcCtD
Afatinib—Infection—Pilocarpine—glaucoma	0.000915	0.00154	CcSEcCtD
Afatinib—Alopecia—Clonidine—glaucoma	0.000915	0.00154	CcSEcCtD
Afatinib—Nausea—Methazolamide—glaucoma	0.000913	0.00153	CcSEcCtD
Afatinib—Dyspnoea—Brimonidine—glaucoma	0.00091	0.00153	CcSEcCtD
Afatinib—Mental disorder—Clonidine—glaucoma	0.000907	0.00152	CcSEcCtD
Afatinib—Dyspepsia—Brimonidine—glaucoma	0.000899	0.00151	CcSEcCtD
Afatinib—Insomnia—Dorzolamide—glaucoma	0.000882	0.00148	CcSEcCtD
Afatinib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000881	0.00148	CcSEcCtD
Afatinib—Fatigue—Brimonidine—glaucoma	0.00088	0.00148	CcSEcCtD
Afatinib—Dyspnoea—Dorzolamide—glaucoma	0.000869	0.00146	CcSEcCtD
Afatinib—Insomnia—Brinzolamide—glaucoma	0.000867	0.00145	CcSEcCtD
Afatinib—Muscle spasms—Clonidine—glaucoma	0.000867	0.00145	CcSEcCtD
Afatinib—Dyspnoea—Travoprost—glaucoma	0.000866	0.00145	CcSEcCtD
Afatinib—Dyspepsia—Dorzolamide—glaucoma	0.000858	0.00144	CcSEcCtD
Afatinib—Upper respiratory tract infection—Timolol—glaucoma	0.000855	0.00144	CcSEcCtD
Afatinib—Dyspnoea—Brinzolamide—glaucoma	0.000855	0.00143	CcSEcCtD
Afatinib—Dyspepsia—Travoprost—glaucoma	0.000855	0.00143	CcSEcCtD
Afatinib—Asthenia—Apraclonidine—glaucoma	0.000853	0.00143	CcSEcCtD
Afatinib—Decreased appetite—Dorzolamide—glaucoma	0.000848	0.00142	CcSEcCtD
Afatinib—Dyspepsia—Brinzolamide—glaucoma	0.000844	0.00142	CcSEcCtD
Afatinib—Eye disorder—Betaxolol—glaucoma	0.000843	0.00141	CcSEcCtD
Afatinib—Pruritus—Apraclonidine—glaucoma	0.000841	0.00141	CcSEcCtD
Afatinib—Body temperature increased—Acetazolamide—glaucoma	0.000841	0.00141	CcSEcCtD
Afatinib—Fatigue—Dorzolamide—glaucoma	0.000841	0.00141	CcSEcCtD
Afatinib—Gastrointestinal disorder—Travoprost—glaucoma	0.000838	0.00141	CcSEcCtD
Afatinib—Fatigue—Travoprost—glaucoma	0.000837	0.0014	CcSEcCtD
Afatinib—Insomnia—Pilocarpine—glaucoma	0.000833	0.0014	CcSEcCtD
Afatinib—Decreased appetite—Brinzolamide—glaucoma	0.000833	0.0014	CcSEcCtD
Afatinib—Weight decreased—Timolol—glaucoma	0.000833	0.0014	CcSEcCtD
Afatinib—Constipation—Travoprost—glaucoma	0.00083	0.00139	CcSEcCtD
Afatinib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000828	0.00139	CcSEcCtD
Afatinib—Asthenia—Bimatoprost—glaucoma	0.000827	0.00139	CcSEcCtD
Afatinib—Fatigue—Brinzolamide—glaucoma	0.000826	0.00139	CcSEcCtD
Afatinib—Dyspnoea—Pilocarpine—glaucoma	0.000821	0.00138	CcSEcCtD
Afatinib—Pruritus—Bimatoprost—glaucoma	0.000816	0.00137	CcSEcCtD
Afatinib—Diarrhoea—Apraclonidine—glaucoma	0.000814	0.00137	CcSEcCtD
Afatinib—Mediastinal disorder—Betaxolol—glaucoma	0.000813	0.00136	CcSEcCtD
Afatinib—Dyspepsia—Pilocarpine—glaucoma	0.000811	0.00136	CcSEcCtD
Afatinib—Decreased appetite—Pilocarpine—glaucoma	0.000801	0.00134	CcSEcCtD
Afatinib—Conjunctivitis—Timolol—glaucoma	0.000798	0.00134	CcSEcCtD
Afatinib—Alopecia—Betaxolol—glaucoma	0.000797	0.00134	CcSEcCtD
Afatinib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000795	0.00133	CcSEcCtD
Afatinib—Mental disorder—Betaxolol—glaucoma	0.00079	0.00133	CcSEcCtD
Afatinib—Constipation—Pilocarpine—glaucoma	0.000788	0.00132	CcSEcCtD
Afatinib—Cough—Clonidine—glaucoma	0.000787	0.00132	CcSEcCtD
Afatinib—Dizziness—Apraclonidine—glaucoma	0.000786	0.00132	CcSEcCtD
Afatinib—Malnutrition—Betaxolol—glaucoma	0.000785	0.00132	CcSEcCtD
Afatinib—Epistaxis—Timolol—glaucoma	0.000774	0.0013	CcSEcCtD
Afatinib—Body temperature increased—Dorzolamide—glaucoma	0.000771	0.00129	CcSEcCtD
Afatinib—Dysgeusia—Betaxolol—glaucoma	0.000769	0.00129	CcSEcCtD
Afatinib—Asthenia—Acetazolamide—glaucoma	0.000763	0.00128	CcSEcCtD
Afatinib—Dizziness—Bimatoprost—glaucoma	0.000762	0.00128	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000762	0.00128	CcSEcCtD
Afatinib—Vomiting—Apraclonidine—glaucoma	0.000756	0.00127	CcSEcCtD
Afatinib—Muscle spasms—Betaxolol—glaucoma	0.000755	0.00127	CcSEcCtD
Afatinib—Dermatitis—Apraclonidine—glaucoma	0.000749	0.00126	CcSEcCtD
Afatinib—Headache—Apraclonidine—glaucoma	0.000745	0.00125	CcSEcCtD
Afatinib—Asthenia—Brimonidine—glaucoma	0.000733	0.00123	CcSEcCtD
Afatinib—Infection—Clonidine—glaucoma	0.000731	0.00123	CcSEcCtD
Afatinib—Body temperature increased—Pilocarpine—glaucoma	0.000728	0.00122	CcSEcCtD
Afatinib—Diarrhoea—Acetazolamide—glaucoma	0.000728	0.00122	CcSEcCtD
Afatinib—Rash—Bimatoprost—glaucoma	0.000727	0.00122	CcSEcCtD
Afatinib—Dermatitis—Bimatoprost—glaucoma	0.000726	0.00122	CcSEcCtD
Afatinib—Connective tissue disorder—Timolol—glaucoma	0.000724	0.00121	CcSEcCtD
Afatinib—Pruritus—Brimonidine—glaucoma	0.000722	0.00121	CcSEcCtD
Afatinib—Headache—Bimatoprost—glaucoma	0.000722	0.00121	CcSEcCtD
Afatinib—Nervous system disorder—Clonidine—glaucoma	0.000722	0.00121	CcSEcCtD
Afatinib—Skin disorder—Clonidine—glaucoma	0.000715	0.0012	CcSEcCtD
Afatinib—Nausea—Apraclonidine—glaucoma	0.000706	0.00119	CcSEcCtD
Afatinib—Dizziness—Acetazolamide—glaucoma	0.000703	0.00118	CcSEcCtD
Afatinib—Asthenia—Dorzolamide—glaucoma	0.0007	0.00117	CcSEcCtD
Afatinib—Asthenia—Travoprost—glaucoma	0.000697	0.00117	CcSEcCtD
Afatinib—Pruritus—Dorzolamide—glaucoma	0.00069	0.00116	CcSEcCtD
Afatinib—Eye disorder—Timolol—glaucoma	0.000688	0.00116	CcSEcCtD
Afatinib—Asthenia—Brinzolamide—glaucoma	0.000688	0.00115	CcSEcCtD
Afatinib—Pruritus—Travoprost—glaucoma	0.000687	0.00115	CcSEcCtD
Afatinib—Cough—Betaxolol—glaucoma	0.000685	0.00115	CcSEcCtD
Afatinib—Nausea—Bimatoprost—glaucoma	0.000685	0.00115	CcSEcCtD
Afatinib—Pruritus—Brinzolamide—glaucoma	0.000678	0.00114	CcSEcCtD
Afatinib—Vomiting—Acetazolamide—glaucoma	0.000676	0.00113	CcSEcCtD
Afatinib—Dizziness—Brimonidine—glaucoma	0.000675	0.00113	CcSEcCtD
Afatinib—Diarrhoea—Dorzolamide—glaucoma	0.000667	0.00112	CcSEcCtD
Afatinib—Headache—Acetazolamide—glaucoma	0.000666	0.00112	CcSEcCtD
Afatinib—Insomnia—Clonidine—glaucoma	0.000665	0.00112	CcSEcCtD
Afatinib—Diarrhoea—Travoprost—glaucoma	0.000664	0.00111	CcSEcCtD
Afatinib—Mediastinal disorder—Timolol—glaucoma	0.000664	0.00111	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000664	0.00111	CcSEcCtD
Afatinib—Asthenia—Pilocarpine—glaucoma	0.000661	0.00111	CcSEcCtD
Afatinib—Dyspnoea—Clonidine—glaucoma	0.000656	0.0011	CcSEcCtD
Afatinib—Diarrhoea—Brinzolamide—glaucoma	0.000656	0.0011	CcSEcCtD
Afatinib—Pruritus—Pilocarpine—glaucoma	0.000652	0.00109	CcSEcCtD
Afatinib—Alopecia—Timolol—glaucoma	0.000651	0.00109	CcSEcCtD
Afatinib—Mental disorder—Timolol—glaucoma	0.000645	0.00108	CcSEcCtD
Afatinib—Dizziness—Dorzolamide—glaucoma	0.000645	0.00108	CcSEcCtD
Afatinib—Rash—Brimonidine—glaucoma	0.000644	0.00108	CcSEcCtD
Afatinib—Dermatitis—Brimonidine—glaucoma	0.000643	0.00108	CcSEcCtD
Afatinib—Dizziness—Travoprost—glaucoma	0.000642	0.00108	CcSEcCtD
Afatinib—Malnutrition—Timolol—glaucoma	0.000641	0.00108	CcSEcCtD
Afatinib—Headache—Brimonidine—glaucoma	0.00064	0.00107	CcSEcCtD
Afatinib—Decreased appetite—Clonidine—glaucoma	0.00064	0.00107	CcSEcCtD
Afatinib—Infection—Betaxolol—glaucoma	0.000636	0.00107	CcSEcCtD
Afatinib—Gastrointestinal disorder—Clonidine—glaucoma	0.000635	0.00107	CcSEcCtD
Afatinib—Fatigue—Clonidine—glaucoma	0.000634	0.00106	CcSEcCtD
Afatinib—Dizziness—Brinzolamide—glaucoma	0.000634	0.00106	CcSEcCtD
Afatinib—Nausea—Acetazolamide—glaucoma	0.000632	0.00106	CcSEcCtD
Afatinib—Diarrhoea—Pilocarpine—glaucoma	0.00063	0.00106	CcSEcCtD
Afatinib—Constipation—Clonidine—glaucoma	0.000629	0.00106	CcSEcCtD
Afatinib—Nervous system disorder—Betaxolol—glaucoma	0.000628	0.00105	CcSEcCtD
Afatinib—Dysgeusia—Timolol—glaucoma	0.000628	0.00105	CcSEcCtD
Afatinib—Skin disorder—Betaxolol—glaucoma	0.000622	0.00104	CcSEcCtD
Afatinib—Vomiting—Dorzolamide—glaucoma	0.00062	0.00104	CcSEcCtD
Afatinib—Rash—Dorzolamide—glaucoma	0.000615	0.00103	CcSEcCtD
Afatinib—Dermatitis—Dorzolamide—glaucoma	0.000614	0.00103	CcSEcCtD
Afatinib—Rash—Travoprost—glaucoma	0.000612	0.00103	CcSEcCtD
Afatinib—Dermatitis—Travoprost—glaucoma	0.000612	0.00103	CcSEcCtD
Afatinib—Headache—Dorzolamide—glaucoma	0.000611	0.00103	CcSEcCtD
Afatinib—Vomiting—Brinzolamide—glaucoma	0.00061	0.00102	CcSEcCtD
Afatinib—Dizziness—Pilocarpine—glaucoma	0.000609	0.00102	CcSEcCtD
Afatinib—Headache—Travoprost—glaucoma	0.000608	0.00102	CcSEcCtD
Afatinib—Nausea—Brimonidine—glaucoma	0.000606	0.00102	CcSEcCtD
Afatinib—Rash—Brinzolamide—glaucoma	0.000604	0.00101	CcSEcCtD
Afatinib—Dermatitis—Brinzolamide—glaucoma	0.000604	0.00101	CcSEcCtD
Afatinib—Headache—Brinzolamide—glaucoma	0.000601	0.00101	CcSEcCtD
Afatinib—Vomiting—Pilocarpine—glaucoma	0.000586	0.000983	CcSEcCtD
Afatinib—Body temperature increased—Clonidine—glaucoma	0.000582	0.000976	CcSEcCtD
Afatinib—Rash—Pilocarpine—glaucoma	0.000581	0.000975	CcSEcCtD
Afatinib—Dermatitis—Pilocarpine—glaucoma	0.00058	0.000974	CcSEcCtD
Afatinib—Insomnia—Betaxolol—glaucoma	0.000579	0.000972	CcSEcCtD
Afatinib—Nausea—Dorzolamide—glaucoma	0.000579	0.000972	CcSEcCtD
Afatinib—Headache—Pilocarpine—glaucoma	0.000577	0.000969	CcSEcCtD
Afatinib—Nausea—Travoprost—glaucoma	0.000577	0.000968	CcSEcCtD
Afatinib—Dyspnoea—Betaxolol—glaucoma	0.000571	0.000958	CcSEcCtD
Afatinib—Nausea—Brinzolamide—glaucoma	0.000569	0.000955	CcSEcCtD
Afatinib—Dyspepsia—Betaxolol—glaucoma	0.000564	0.000946	CcSEcCtD
Afatinib—Cough—Timolol—glaucoma	0.00056	0.000939	CcSEcCtD
Afatinib—Decreased appetite—Betaxolol—glaucoma	0.000557	0.000934	CcSEcCtD
Afatinib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000553	0.000928	CcSEcCtD
Afatinib—Fatigue—Betaxolol—glaucoma	0.000552	0.000927	CcSEcCtD
Afatinib—Constipation—Betaxolol—glaucoma	0.000548	0.000919	CcSEcCtD
Afatinib—Nausea—Pilocarpine—glaucoma	0.000547	0.000918	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000542	0.00091	CcSEcCtD
Afatinib—Asthenia—Clonidine—glaucoma	0.000528	0.000886	CcSEcCtD
Afatinib—Pruritus—Clonidine—glaucoma	0.000521	0.000874	CcSEcCtD
Afatinib—Infection—Timolol—glaucoma	0.00052	0.000872	CcSEcCtD
Afatinib—Nervous system disorder—Timolol—glaucoma	0.000513	0.000861	CcSEcCtD
Afatinib—Skin disorder—Timolol—glaucoma	0.000508	0.000853	CcSEcCtD
Afatinib—Body temperature increased—Betaxolol—glaucoma	0.000506	0.00085	CcSEcCtD
Afatinib—Diarrhoea—Clonidine—glaucoma	0.000503	0.000845	CcSEcCtD
Afatinib—Dizziness—Clonidine—glaucoma	0.000487	0.000816	CcSEcCtD
Afatinib—Insomnia—Timolol—glaucoma	0.000473	0.000794	CcSEcCtD
Afatinib—Vomiting—Clonidine—glaucoma	0.000468	0.000785	CcSEcCtD
Afatinib—Dyspnoea—Timolol—glaucoma	0.000467	0.000783	CcSEcCtD
Afatinib—Rash—Clonidine—glaucoma	0.000464	0.000778	CcSEcCtD
Afatinib—Dermatitis—Clonidine—glaucoma	0.000463	0.000778	CcSEcCtD
Afatinib—Headache—Clonidine—glaucoma	0.000461	0.000773	CcSEcCtD
Afatinib—Dyspepsia—Timolol—glaucoma	0.000461	0.000773	CcSEcCtD
Afatinib—Asthenia—Betaxolol—glaucoma	0.00046	0.000771	CcSEcCtD
Afatinib—Decreased appetite—Timolol—glaucoma	0.000455	0.000763	CcSEcCtD
Afatinib—Pruritus—Betaxolol—glaucoma	0.000453	0.00076	CcSEcCtD
Afatinib—Gastrointestinal disorder—Timolol—glaucoma	0.000452	0.000758	CcSEcCtD
Afatinib—Fatigue—Timolol—glaucoma	0.000451	0.000757	CcSEcCtD
Afatinib—Diarrhoea—Betaxolol—glaucoma	0.000438	0.000735	CcSEcCtD
Afatinib—Nausea—Clonidine—glaucoma	0.000437	0.000733	CcSEcCtD
Afatinib—Dizziness—Betaxolol—glaucoma	0.000424	0.000711	CcSEcCtD
Afatinib—Body temperature increased—Timolol—glaucoma	0.000414	0.000694	CcSEcCtD
Afatinib—Vomiting—Betaxolol—glaucoma	0.000407	0.000683	CcSEcCtD
Afatinib—Rash—Betaxolol—glaucoma	0.000404	0.000678	CcSEcCtD
Afatinib—Dermatitis—Betaxolol—glaucoma	0.000404	0.000677	CcSEcCtD
Afatinib—Headache—Betaxolol—glaucoma	0.000401	0.000673	CcSEcCtD
Afatinib—Nausea—Betaxolol—glaucoma	0.00038	0.000638	CcSEcCtD
Afatinib—Asthenia—Timolol—glaucoma	0.000375	0.00063	CcSEcCtD
Afatinib—Pruritus—Timolol—glaucoma	0.00037	0.000621	CcSEcCtD
Afatinib—Diarrhoea—Timolol—glaucoma	0.000358	0.000601	CcSEcCtD
Afatinib—Dizziness—Timolol—glaucoma	0.000346	0.000581	CcSEcCtD
Afatinib—Vomiting—Timolol—glaucoma	0.000333	0.000558	CcSEcCtD
Afatinib—Rash—Timolol—glaucoma	0.00033	0.000554	CcSEcCtD
Afatinib—Dermatitis—Timolol—glaucoma	0.00033	0.000553	CcSEcCtD
Afatinib—Headache—Timolol—glaucoma	0.000328	0.00055	CcSEcCtD
Afatinib—Nausea—Timolol—glaucoma	0.000311	0.000522	CcSEcCtD
Afatinib—ERBB2—Signaling Pathways—NTRK2—glaucoma	9.81e-05	0.000246	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CDKN1B—glaucoma	9.77e-05	0.000245	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—VEGFA—glaucoma	9.69e-05	0.000243	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	9.68e-05	0.000243	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NTRK2—glaucoma	9.67e-05	0.000242	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	9.65e-05	0.000242	CbGpPWpGaD
Afatinib—ERBB2—Immune System—C3—glaucoma	9.56e-05	0.000239	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CDKN1B—glaucoma	9.52e-05	0.000239	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—CAV1—glaucoma	9.51e-05	0.000238	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—PTGS2—glaucoma	9.51e-05	0.000238	CbGpPWpGaD
Afatinib—EGFR—Disease—HDAC9—glaucoma	9.47e-05	0.000237	CbGpPWpGaD
Afatinib—ERBB4—Immune System—C3—glaucoma	9.41e-05	0.000236	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CDKN1B—glaucoma	9.38e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP2—glaucoma	9.37e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—Direct p53 effectors—TP53—glaucoma	9.35e-05	0.000234	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—VEGFA—glaucoma	9.34e-05	0.000234	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—C3—glaucoma	9.28e-05	0.000233	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—glaucoma	9.17e-05	0.00023	CbGpPWpGaD
Afatinib—ERBB2—Immune System—BCL2L1—glaucoma	9.15e-05	0.000229	CbGpPWpGaD
Afatinib—LCK—Disease—HDAC9—glaucoma	9.12e-05	0.000229	CbGpPWpGaD
Afatinib—BLK—Immune System—C3—glaucoma	9.06e-05	0.000227	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—FN1—glaucoma	9.05e-05	0.000227	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CDKN1B—glaucoma	9.02e-05	0.000226	CbGpPWpGaD
Afatinib—ERBB4—Immune System—BCL2L1—glaucoma	9.01e-05	0.000226	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—BCL2L1—glaucoma	8.89e-05	0.000223	CbGpPWpGaD
Afatinib—ERBB2—Disease—MTHFR—glaucoma	8.82e-05	0.000221	CbGpPWpGaD
Afatinib—EGFR—Integrated Breast Cancer Pathway—TP53—glaucoma	8.8e-05	0.000221	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—SMO—glaucoma	8.78e-05	0.00022	CbGpPWpGaD
Afatinib—ERBB4—Disease—MTHFR—glaucoma	8.69e-05	0.000218	CbGpPWpGaD
Afatinib—BLK—Immune System—BCL2L1—glaucoma	8.67e-05	0.000217	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	8.54e-05	0.000214	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—glaucoma	8.46e-05	0.000212	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NGFR—glaucoma	8.42e-05	0.000211	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	8.41e-05	0.000211	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—CDKN1B—glaucoma	8.4e-05	0.000211	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NGFR—glaucoma	8.29e-05	0.000208	CbGpPWpGaD
Afatinib—ERBB2—Immune System—BAD—glaucoma	8.29e-05	0.000208	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—VEGFA—glaucoma	8.28e-05	0.000207	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	8.27e-05	0.000207	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—MMP9—glaucoma	8.24e-05	0.000207	CbGpPWpGaD
Afatinib—ERBB2—Disease—APOE—glaucoma	8.22e-05	0.000206	CbGpPWpGaD
Afatinib—LCK—Hemostasis—MMP1—glaucoma	8.17e-05	0.000205	CbGpPWpGaD
Afatinib—ERBB4—Immune System—BAD—glaucoma	8.17e-05	0.000205	CbGpPWpGaD
Afatinib—ERBB2—Disease—CAV1—glaucoma	8.14e-05	0.000204	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—CDKN1B—glaucoma	8.1e-05	0.000203	CbGpPWpGaD
Afatinib—ERBB4—Disease—APOE—glaucoma	8.09e-05	0.000203	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TP53—glaucoma	8.08e-05	0.000203	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—BAD—glaucoma	8.05e-05	0.000202	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RPTOR—glaucoma	8.05e-05	0.000202	CbGpPWpGaD
Afatinib—ERBB4—Disease—CAV1—glaucoma	8.02e-05	0.000201	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—glaucoma	8e-05	0.000201	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NTRK1—glaucoma	8e-05	0.0002	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—C3—glaucoma	7.93e-05	0.000199	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NTRK1—glaucoma	7.88e-05	0.000197	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1A—glaucoma	7.86e-05	0.000197	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	7.86e-05	0.000197	CbGpPWpGaD
Afatinib—BLK—Immune System—BAD—glaucoma	7.86e-05	0.000197	CbGpPWpGaD
Afatinib—LCK—Hemostasis—CAV1—glaucoma	7.83e-05	0.000196	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP2—glaucoma	7.83e-05	0.000196	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NCK2—glaucoma	7.8e-05	0.000195	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SMO—glaucoma	7.76e-05	0.000194	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RPTOR—glaucoma	7.76e-05	0.000194	CbGpPWpGaD
Afatinib—ERBB2—Disease—BAD—glaucoma	7.66e-05	0.000192	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—C3—glaucoma	7.65e-05	0.000192	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—TXN—glaucoma	7.64e-05	0.000191	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—C3—glaucoma	7.62e-05	0.000191	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—BCL2L1—glaucoma	7.59e-05	0.00019	CbGpPWpGaD
Afatinib—ERBB4—Disease—BAD—glaucoma	7.54e-05	0.000189	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NCK2—glaucoma	7.51e-05	0.000188	CbGpPWpGaD
Afatinib—LCK—Hemostasis—FN1—glaucoma	7.46e-05	0.000187	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—VEGFA—glaucoma	7.4e-05	0.000185	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CDKN2B—glaucoma	7.37e-05	0.000185	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—C3—glaucoma	7.34e-05	0.000184	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—BCL2L1—glaucoma	7.32e-05	0.000183	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	7.29e-05	0.000183	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CDKN2B—glaucoma	7.26e-05	0.000182	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NOS3—glaucoma	7.19e-05	0.00018	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CDKN1B—glaucoma	7.17e-05	0.00018	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NTRK2—glaucoma	7.09e-05	0.000178	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EDN1—glaucoma	7.07e-05	0.000177	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—MMP9—glaucoma	7.04e-05	0.000177	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EDN1—glaucoma	6.97e-05	0.000175	CbGpPWpGaD
Afatinib—IRAK1—Immune System—C3—glaucoma	6.91e-05	0.000173	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—BAD—glaucoma	6.88e-05	0.000172	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP2—glaucoma	6.69e-05	0.000168	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—BAD—glaucoma	6.63e-05	0.000166	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HDAC9—glaucoma	6.63e-05	0.000166	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BCL2L1—glaucoma	6.61e-05	0.000166	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—BAD—glaucoma	6.61e-05	0.000166	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NGF—glaucoma	6.5e-05	0.000163	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CA1—glaucoma	6.41e-05	0.000161	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NGF—glaucoma	6.4e-05	0.00016	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HDAC9—glaucoma	6.39e-05	0.00016	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—BAD—glaucoma	6.37e-05	0.00016	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—VEGFA—glaucoma	6.33e-05	0.000158	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CTSA—glaucoma	6.21e-05	0.000156	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	6.19e-05	0.000155	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—C3—glaucoma	6.18e-05	0.000155	CbGpPWpGaD
Afatinib—ERBB2—Disease—NOS3—glaucoma	6.15e-05	0.000154	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1A—glaucoma	6.15e-05	0.000154	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—C3—glaucoma	6.09e-05	0.000153	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NGFR—glaucoma	6.09e-05	0.000153	CbGpPWpGaD
Afatinib—ERBB4—Disease—NOS3—glaucoma	6.06e-05	0.000152	CbGpPWpGaD
Afatinib—IRAK1—Immune System—BAD—glaucoma	5.99e-05	0.00015	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTT1—glaucoma	5.93e-05	0.000148	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NOS3—glaucoma	5.92e-05	0.000148	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—MMP9—glaucoma	5.88e-05	0.000147	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CA2—glaucoma	5.86e-05	0.000147	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	5.86e-05	0.000147	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—EDN1—glaucoma	5.79e-05	0.000145	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NTRK1—glaucoma	5.78e-05	0.000145	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CDKN1B—glaucoma	5.77e-05	0.000145	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—APOE—glaucoma	5.75e-05	0.000144	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CAV1—glaucoma	5.7e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CDKN1B—glaucoma	5.69e-05	0.000143	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—APOE—glaucoma	5.67e-05	0.000142	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—glaucoma	5.63e-05	0.000141	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CAV1—glaucoma	5.61e-05	0.000141	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CDKN1B—glaucoma	5.61e-05	0.000141	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—glaucoma	5.54e-05	0.000139	CbGpPWpGaD
Afatinib—BLK—Immune System—CDKN1B—glaucoma	5.47e-05	0.000137	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—FN1—glaucoma	5.43e-05	0.000136	CbGpPWpGaD
Afatinib—ABL1—Immune System—C3—glaucoma	5.41e-05	0.000135	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—BAD—glaucoma	5.36e-05	0.000134	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—FN1—glaucoma	5.34e-05	0.000134	CbGpPWpGaD
Afatinib—ERBB2—Disease—CDKN1B—glaucoma	5.33e-05	0.000134	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN2B—glaucoma	5.33e-05	0.000134	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—VEGFA—glaucoma	5.28e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—BAD—glaucoma	5.28e-05	0.000132	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1A—glaucoma	5.26e-05	0.000132	CbGpPWpGaD
Afatinib—ERBB4—Disease—CDKN1B—glaucoma	5.25e-05	0.000132	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMO—glaucoma	5.19e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—VEGFA—glaucoma	5.18e-05	0.00013	CbGpPWpGaD
Afatinib—ABL1—Immune System—BCL2L1—glaucoma	5.18e-05	0.00013	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EDN1—glaucoma	5.11e-05	0.000128	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN2B—glaucoma	5.09e-05	0.000128	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1A—glaucoma	5.07e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—C3—glaucoma	5.06e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—MMP9—glaucoma	5.03e-05	0.000126	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMO—glaucoma	5e-05	0.000125	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN2B—glaucoma	4.9e-05	0.000123	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	4.87e-05	0.000122	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CDKN1B—glaucoma	4.79e-05	0.00012	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NTRK2—glaucoma	4.74e-05	0.000119	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP1B1—glaucoma	4.72e-05	0.000118	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCA1—glaucoma	4.72e-05	0.000118	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NGF—glaucoma	4.7e-05	0.000118	CbGpPWpGaD
Afatinib—ABL1—Immune System—BAD—glaucoma	4.69e-05	0.000118	CbGpPWpGaD
Afatinib—EGFR—Immune System—C3—glaucoma	4.62e-05	0.000116	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CDKN1B—glaucoma	4.62e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDKN1B—glaucoma	4.6e-05	0.000115	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NTRK2—glaucoma	4.57e-05	0.000115	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—glaucoma	4.53e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—glaucoma	4.51e-05	0.000113	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—C3—glaucoma	4.47e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Immune System—C3—glaucoma	4.45e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDKN1B—glaucoma	4.44e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2L1—glaucoma	4.42e-05	0.000111	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOS3—glaucoma	4.31e-05	0.000108	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—glaucoma	4.27e-05	0.000107	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—glaucoma	4.27e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2L1—glaucoma	4.26e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOS3—glaucoma	4.25e-05	0.000106	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	4.18e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDKN1B—glaucoma	4.17e-05	0.000105	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—glaucoma	4.16e-05	0.000104	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TXN—glaucoma	4.13e-05	0.000104	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CAV1—glaucoma	4.12e-05	0.000103	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—glaucoma	4.11e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NGFR—glaucoma	4.07e-05	0.000102	CbGpPWpGaD
Afatinib—EGFR—Immune System—BAD—glaucoma	4.01e-05	0.0001	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—glaucoma	3.97e-05	9.95e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CAV1—glaucoma	3.94e-05	9.86e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FN1—glaucoma	3.92e-05	9.83e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NGFR—glaucoma	3.92e-05	9.83e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—glaucoma	3.92e-05	9.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—BAD—glaucoma	3.88e-05	9.71e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—glaucoma	3.87e-05	9.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NTRK1—glaucoma	3.87e-05	9.69e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BAD—glaucoma	3.86e-05	9.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—glaucoma	3.83e-05	9.59e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CAV1—glaucoma	3.79e-05	9.5e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTM1—glaucoma	3.77e-05	9.46e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CDKN1B—glaucoma	3.73e-05	9.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NTRK1—glaucoma	3.73e-05	9.34e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—BAD—glaucoma	3.7e-05	9.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	3.68e-05	9.23e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CDKN1B—glaucoma	3.68e-05	9.22e-05	CbGpPWpGaD
Afatinib—LCK—Disease—BAD—glaucoma	3.57e-05	8.94e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN2B—glaucoma	3.56e-05	8.93e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—glaucoma	3.46e-05	8.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN2B—glaucoma	3.43e-05	8.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EDN1—glaucoma	3.42e-05	8.57e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—glaucoma	3.41e-05	8.53e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—glaucoma	3.34e-05	8.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EDN1—glaucoma	3.3e-05	8.26e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1B—glaucoma	3.27e-05	8.19e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—glaucoma	3.22e-05	8.08e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTT1—glaucoma	3.2e-05	8.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NGF—glaucoma	3.14e-05	7.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—glaucoma	3.12e-05	7.81e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—glaucoma	3.11e-05	7.78e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—glaucoma	3.11e-05	7.78e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—glaucoma	3.08e-05	7.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—glaucoma	3.06e-05	7.66e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NGF—glaucoma	3.03e-05	7.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C3—glaucoma	2.99e-05	7.49e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—glaucoma	2.98e-05	7.46e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C3—glaucoma	2.88e-05	7.21e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—glaucoma	2.87e-05	7.18e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—glaucoma	2.79e-05	7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—glaucoma	2.78e-05	6.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—glaucoma	2.76e-05	6.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—glaucoma	2.72e-05	6.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—glaucoma	2.7e-05	6.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—glaucoma	2.69e-05	6.74e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—glaucoma	2.68e-05	6.72e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—glaucoma	2.66e-05	6.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—glaucoma	2.62e-05	6.57e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—glaucoma	2.62e-05	6.57e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BAD—glaucoma	2.59e-05	6.49e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—glaucoma	2.58e-05	6.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ABCA1—glaucoma	2.55e-05	6.4e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—glaucoma	2.55e-05	6.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—glaucoma	2.53e-05	6.33e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—glaucoma	2.5e-05	6.26e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BAD—glaucoma	2.5e-05	6.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—glaucoma	2.48e-05	6.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—glaucoma	2.35e-05	5.88e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—glaucoma	2.33e-05	5.83e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—glaucoma	2.31e-05	5.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—glaucoma	2.24e-05	5.63e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—glaucoma	2.13e-05	5.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—glaucoma	2.08e-05	5.22e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—glaucoma	2.04e-05	5.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—glaucoma	2.01e-05	5.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—glaucoma	1.8e-05	4.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—glaucoma	1.8e-05	4.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—glaucoma	1.74e-05	4.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—glaucoma	1.7e-05	4.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—glaucoma	1.68e-05	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—glaucoma	1.67e-05	4.19e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—glaucoma	1.66e-05	4.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—glaucoma	1.61e-05	4.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—glaucoma	1.5e-05	3.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—glaucoma	1.45e-05	3.62e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—glaucoma	1.26e-05	3.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—glaucoma	1.15e-05	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—glaucoma	1.13e-05	2.84e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—glaucoma	1.09e-05	2.74e-05	CbGpPWpGaD
